Brief report

Two distinct pathways regulate platelet phosphatidylserine exposure and procoagulant function

*Simone M. Schoenwaelder,† Yuping Yuan,* Emma C. Josefsson, Michael J. White, Yu Yao, Kylie D. Mason, Lorraine A. O’Reilly, Katya J. Henley, Akiko Ono, Sarah Hisaio, Abbey Willcox, Andrew W. Roberts, David C. S. Huang, Hatem H. Salem, †Benjamin T. Kile, and †Shaun P. Jackson

Procoagulant platelets exhibit hallmark features of apoptotic cells, including membrane blebbing, microvesiculation, and phosphatidylserine (PS) exposure. Although platelets possess many well-known apoptotic regulators, their role in regulating the procoagulant function of platelets is unclear. To clarify this, we investigated the consequence of removing the essential mediators of apoptosis, Bak and Bax, or directly inducing apoptosis with the BH3 mimetic compound ABT-737. Treatment of platelets with ABT-737 triggered PS exposure and a marked increase in thrombin generation in vitro. This increase in procoagulant function was Bak/Bax- and caspase-dependent, but it was unaffected by inhibitors of platelet activation or by chelating extracellular calcium. In contrast, agonist-induced platelet procoagulant function was unchanged in Bak-/-Bax-/- or caspase inhibitor–treated platelets, but it was completely eliminated by extracellular calcium chelators or inhibitors of platelet activation. These studies show the existence of 2 distinct pathways regulating the procoagulant function of platelets. (Blood. 2009;114:663-666)

Introduction

The hemostatic and prothrombotic function of platelets is critically dependent on 2 key properties: (1) their ability to adhere and aggregate at sites of vascular injury and (2) their ability to support blood coagulation, necessary for thrombin generation and fibrin formation (platelet procoagulant function, referring to the ability of platelets to support thrombin generation). The conversion of activated platelets to a procoagulant state is associated with specific biochemical and morphologic changes, some of which are similar to those occurring in apoptotic cells,1,2 including caspase activation, proteolytic processing of cytoskeletal elements, surface exposure of phosphatidylserine (PS), and membrane contraction, blebbing, and microvesiculation.

Platelets contain many well-known apoptotic regulators, including members of the Bcl-2 family protein, and downstream effectors such as caspases. It was recently shown that prosurvival Bcl-XL maintains platelet viability, primarily by restraining the proapoptotic function of Bak.3 Ex vivo treatment of platelets with the BH3 mimetic compound ABT-737, a potent inhibitor of Bcl-xL,4 triggers mitochondrial damage, caspase activation, and membrane externalization of PS.5,6 The relationship between platelet apoptosis and the activation-dependent pathways that drive platelet procoagulant activity is unclear. Several groups have suggested that Bcl-2 family proteins can be posttranscriptionally regulated in agonist-stimulated platelets.3,5 It has also been reported that Bcl-xL levels decline in stored platelets,10,11 and that this coincides with an increase in PS exposure and increased platelet procoagulant activity.5,6,12,13 Taken together, these findings suggest that the apoptotic machinery may regulate the procoagulant function of platelets.

In this study, we have investigated whether direct induction of apoptosis stimulates platelet procoagulant activity, independent of platelet activation, and whether the apoptotic machinery in platelets plays an important role in regulating agonist-induced platelet procoagulant function.

Methods

The materials and methods used in this study are described in supplemental material (available on the Blood website; see the Supplemental Materials link at the top of the online article). All animal studies were approved by the animal ethics committee at the Alfred Medical Research and Education Precinct (Melbourne, Australia). All procedures involving collection of human blood were approved by the Monash Committee on Ethics in Research, and informed consent was obtained in accordance with the Declaration of Helsinki.

Results and discussion

Caspases are activated in apoptotic platelets independent of platelet activation

Membrane fragmentation (referring to blebbing and loss of membrane integrity, as observed through differential interference contrast [DIC] microscopy and scanning electron microscopy), microvesiculation, and the exposure of PS on the surface of agonist-stimulated platelets requires calcium influx and is associated with
the proteolytic cleavage of a range of cellular substrates. Prominent among these are the cytoskeletal proteins, filamin-1 and gelsolin, that are cleaved by the calcium-activated thiol protease, calpain. Induction of apoptosis in washed human platelets with extracellular calcium (Figure 1A EGTA), calpain inhibitors (supplemental Figure 1A), filamin cleavage, as described in “Methods.” Immunoblots are representative of 3 independent experiments. (C-F) The ability of human (C-E) or PAR4−/− mouse platelets (F) to promote thrombin generation was assessed with the use of a Thrombinoscope (Thromboscope BV), as described in “Methods.” Line graphs (C-E) are taken from 1 representative of 3 independent experiments. Histograms (D-F) represent the means ± SEM (n = 3; *P < .05; **P < .005).

Aptotic platelets exhibit procoagulant activity

PS exposure on the surface of activated platelets is essential for the membrane assembly of coagulation factor complexes, including the tenase and prothrombinase complexes, necessary for thrombin generation. Whether PS exposure alone is sufficient to support blood coagulation, independent of other events linked to platelet activation, has not been defined. To investigate this, ABT-737–treated platelets were incubated with recalcified platelet-poor plasma, and thrombin generation was quantified in real time by monitoring cleavage of the fluorogenic thrombin substrate, Fluorosubstrate (Thromboscope BV). As shown in Figure 1 and supplemental Figure 2, ABT-737–treated platelets supported robust thrombin generation, similar in rate and extent to that induced by
calcium ionophore A23187 or CRP (Figure 1C-E; supplemental Figure 2), in the absence of any apparent signs of platelet activation, as assessed by P-selectin expression, integrin αIIbβ3 activation (supplemental Figure 3), and increases in cytosolic calcium (data not shown). This increase in procoagulant activity was independent of platelet costimulation by enzymatically generated thrombin, because PAR4+/− platelets, which are completely unresponsive to thrombin, were equally effective at supporting thrombin generation after ABT-737 treatment (Figure 1F). Furthermore, the potent platelet activation inhibitors, PGE1 and theophylline (PGE1/Theo) abolished CRP-induced thrombin generation but had no significant inhibitory effect on ABT-737–induced thrombin generation (Figure 1C-E). In contrast, Q-VD-Oph abolished ABT-737–induced thrombin generation but had no effect on CRP-stimulated thrombin generation (Figure 2C-D).

**PS exposure by apoptotic platelets requires Bak and Bax**

Because Bak and Bax are the central mediators of the intrinsic apoptotic pathway, we investigated their role in mediating platelet PS exposure and thrombin generation induced by ABT-737 or agonist. In mouse platelets, loss of Bak alone (Bak−/− Bak+/+) resulted in a 10% decrease in ABT-737–induced PS exposure, whereas the additional loss of one Bax allele (Bak−/− Bax+/+) inhibited ABT-737–induced PS exposure by approximately 60%. Bak−/−/Bax−/− platelets were completely resistant to the effects of ABT-737 (Figure 2A). In contrast, stimulation of Bak−/− Bax+/+, Bak−/−/Bax−/−, or Bak−/−/Bax−/− platelets with either calcium ionophore A23187 (data not shown) or a combination of CRP and thrombin was associated with normal levels of PS expression and thrombin generation (Figure 2A-B). The caspase inhibitor Q-VD-Oph prevented ABT-737–induced PS exposure, consistent with a reduction in thrombin generation (Figure 2C-E), but had no effect on the procoagulant activity of platelets stimulated with calcium ionophore A23187 or physiologic agonists (data not shown; Figure 2D). In both agonist-stimulated and apoptotic platelets thrombin generation was dependent on surface exposure of PS, because it was completely inhibited by the addition of purified annexin V (supplemental Figure 2C).

**Conclusions**

Our findings show that 2 distinct pathways can regulate PS exposure and the procoagulant activity of platelets in vitro: (1) a calcium-dependent, caspase-independent pathway induced by physiologic agonists and (2) a Bak/Bax-caspase–mediated pathway independent of platelet activation. Moreover, we have shown that, although agonist-induced procoagulant (PS+) platelets exhibit characteristics of apoptotic cells, the processes regulating their formation are distinct from those regulating platelet apoptosis.
Whether PS exposure on the surface of apoptotic platelets has any relevance to thrombin generation in vivo, or whether it represents a signal for the clearance of platelets at steady state, remains to be established. Notably, in preliminary studies we have shown that ABT-737–treated platelets have reduced adhesive function and are rapidly cleared from the circulation after infusion into healthy mice, features that may limit any prothrombotic potential in vivo. Nonetheless, our demonstration that platelet procoagulant function can occur independently of platelet activation is of particular interest as BH3 mimetic compounds enter clinical trials for the treatment of malignant diseases.

Acknowledgments

We thank S. Sturgeon, J. Corbin, J. Blyth, A. Carmagnac, K. Lowes, and the WEHI Bioservices staff for outstanding technical assistance.

This work was supported by the National Heart Foundation of Australia (Melbourne, Australia; project grant G 06M 2617 to S.M.S.), the National Health and Medical Research Council of Australia (Canberra, Australia; project grant 516725; program grants 461221, 461219, IRIISS 361646; and fellowships to S.P.J., B.T.K., L.A.O., A.W.R., and D.C.S.H.), the Australian Research Council (Canberra, Australia; QEII fellowship to B.T.K.), the Victorian Cancer Agency (Carlton, Australia; fellowship to K.D.M.), a Victorian State Government OIS grant, the Cancer Council of Victoria (Carlton, Australia), the Sylvia and Charles Viertel Charitable Foundation (Melbourne, Australia; fellowship to B.T.K.), the Swedish Research Council (Stockholm, Sweden; fellowship to E.C.J.), and the Leukemia & Lymphoma Society (White Plains, NY; fellowship to E.C.J.; SCOR 7015-02).

Authorship

Contribution: S.M.S. designed and performed the research, analyzed data, and wrote the paper; Y. Yuan, E.C.J., and M.J.W. performed research and analyzed data; Y. Yao, K.D.M., L.A.O., K.I.H., A.O., S.H., and A.W. performed research; A.W.R. and H.H.S. designed research and analyzed data; D.C.S.H. designed research, analyzed data, and contributed vital new reagents; and B.T.K. and S.P.J. designed research, analyzed data, and wrote the paper.

Conflict-of-interest disclosure: The authors declare no competing financial interests.

Correspondence: Shaun P. Jackson, Australian Centre for Blood Diseases, Monash University, 6th Level Burnet Bldg, 89 Commercial Rd, Melbourne, Victoria 3004, Australia, e-mail: shaun.jackson@med.monash.edu.au; or Benjamin T. Kile, Division of Molecular Medicine, The Walter or Eliza Hall Institute of Medical Research, 1 G Royal Parade, Parkville, Victoria 3052, Australia; e-mail: kile@wehi.edu.au.

References

Two distinct pathways regulate platelet phosphatidylserine exposure and procoagulant function

Simone M. Schoenwaelder, Yuping Yuan, Emma C. Josefsson, Michael J. White, Yu Yao, Kylie D. Mason, Lorraine A. O'Reilly, Katya J. Henley, Akiko Ono, Sarah Hsiao, Abbey Willcox, Andrew W. Roberts, David C. S. Huang, Hatem H. Salem, Benjamin T. Kile and Shaun P. Jackson

Updated information and services can be found at:
http://www.bloodjournal.org/content/114/3/663.full.html

Articles on similar topics can be found in the following Blood collections
  Brief Reports (1931 articles)
  Platelets and Thrombopoiesis (722 articles)
  Thrombosis and Hemostasis (1061 articles)

Information about reproducing this article in parts or in its entirety may be found online at:
http://www.bloodjournal.org/site/misc/rights.xhtml#repub_requests

Information about ordering reprints may be found online at:
http://www.bloodjournal.org/site/misc/rights.xhtml#reprints

Information about subscriptions and ASH membership may be found online at:
http://www.bloodjournal.org/site/subscriptions/index.xhtml